<DOC>
	<DOCNO>NCT00576017</DOCNO>
	<brief_summary>To show , use analgesic WHO scale , fentanyl-TTS may directly use treat moderate severe cancer pain patient treat NSAIDs , acetaminophen , metamizole ( first step drug ) avoid second step , may least effective safe currently use second step drug , minor opioids .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness Fentanyl-TTS Compared Weak Opioids Patients With Moderate Severe Chronic Cancer Pain Previously Treated With NSAIDS ( Non-steroidal Anti-inflammatory Drugs ) .</brief_title>
	<detailed_description>This study multicenter , randomize ( study drug assign chance ) , open-label , nationwide study . Patients moderate severe chronic pain due oncological disease ( VAS &gt; 5 ) meeting inclusion exclusion criterion randomize treatment fentanyl-TTS ( transdermal patch , initial dosage : 25µg/h patch every 3 day , experimental drug ) minor opioids ( Tramadol , initial dosage 200mg/day Dihydrocodeine initial dosage 120mg/day , control arm ) . The follow-up drug administration two month , control perform every 7 day , except first Day 4 . If pain control ( VAS &lt; 3 ) , investigator could increase dose relevant drug ( accord data sheet ) . The primary endpoint control pain treatment . Pain assess visual analogue scale . Pain severity assess follow-up visit . The secondary endpoint ass advantage use fentanyl-TTS first step WHO analgesic ladder compare minor opioids . These advantage assess base incidence side effect associate treatment opioids treatment follow assessed table common side effect : nausea , vomit , constipation drowsiness ( WHO ) severity , quantity support drug require patient cope side effect occur , adverse event relate study drug , percentage patient discontinue switch treatment due side effect . Fentanyl , dosage form : 25µg/h , 50µg/h 100µg/h . Transdermal patch ( initial dosage : 25µg/h patch every 3 day ) . Tramadol , dosage form : 100mg , 150mg 200mg , ( initial dosage : 200mg/day ) . Dihydrocodeine , dosage form : 60mg , 90mg 120mg , ( initial dosage : 120mg/day ) . If pain control ( VAS &lt; 3 ) , investigator could increase dose relevant drug . The follow-up drug administration two month , control perform every 7 day .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Patients moderate severe chronic pain due oncological condition , define VAS = &gt; 5 , treat first step drug , either NSAIDs acetaminophen metamizole ( dose first step drug require switch treatment leave physician 's discretion ) Patients documented histological diagnosis cancer . Patients whose pain neuropathic component Patients treat opioids 2 month prior study entry Patients dermatological disease , history allergy hypersensitivity fentanyl adhesive component prevent use patch Patients history cardiac , CNS , respiratory disease prevent participation study investigator 's judgment Patients kidney liver failure contraindicate use opioids base medical criterion Pregnant woman woman childbearing age use effective contraceptive method throughout study Patients surgery plan study Patients participate time another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Cancer pain treatment</keyword>
	<keyword>Fentanyl TTS</keyword>
	<keyword>Dihydrocodeine</keyword>
	<keyword>Tramadol</keyword>
	<keyword>Cancer pain</keyword>
	<keyword>Durogesic</keyword>
	<keyword>Ultram</keyword>
</DOC>